GLPG - Galapagos NV
After hours:
| Previous Close | 41.00 |
| Open | 41.54 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1200 |
| Day's Range | 41.09 - 41.84 |
| 52 Week Range | 36.17 - 58.67 |
| Volume | |
| Avg. Volume | 268,198 |
| Market Cap | 2.766B |
| Beta (5Y Monthly) | 0.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.89 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.74 |
Simply Wall St.While public companies own 25% of Galapagos NV (AMS:GLPG), retail investors are its largest shareholders with 45% ownership
Key Insights The considerable ownership by retail investors in Galapagos indicates that they collectively have a...
GlobeNewswireGalapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and, if approved, has the potential to be the first selective oral TYK2 inhibitor in dermatomyositis Mechelen, Belgium; 23 May 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis (DM) trial with GLPG3667
- GlobeNewswire
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
9 poster presentations and 3 abstracts publications reinforce Galapagos' commitment to immunology and the rheumatoid arthritis (RA) patient and healthcare professional communityNew analyses will be presented from long-term extension studies providing insights into filgotinib's effectiveness and safetyInterim baseline characteristics, effectiveness and safety outcomes will be published online from the real-world FILOSOPHY study in RA patients Mechelen, Belgium; 22 May 2023, 22:01 CET; Galapagos N
- Simply Wall St.
Galapagos (AMS:GLPG) shareholders have endured a 82% loss from investing in the stock three years ago
Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So consider, for a...
- GlobeNewswire
Galapagos creates new subscription right plans
Mechelen, Belgium; 5 May 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,975,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 5 May 2023, the Board of Directors of Galapagos approved “Subscription Right Plan 2023 BE”, intended for members of personnel of the company and its Belgian subsidiary, “Subscription Rig
- GlobeNewswire
Galapagos announces first quarter 2023 financial results
Progress with immunology and oncology pipeline: First patients dosed in pivotal Phase 3 OLINGUITO study with filgotinib in axial spondyloarthritis (AxSpA)Clinical sites opened to start patient recruitment in Phase 2 GALARISSO study with TYK2 inhibitor product candidate, GLPG3667, in dermatomyositis (DM)On track to report topline results from two CAR-T Phase 1/2 studies in hemato-oncology mid-2023Further expanding CAR-T point-of-care network in Europe, with IND filing in the US expected before ye
- GlobeNewswire
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
Mechelen, Belgium; 2 May 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the departure of Bart Filius, President, Chief Operating Officer and Chief Financial Officer. Bart Filius joined Galapagos in 2014 as Chief Financial Officer and subsequently took on the responsibility as Chief Operating Officer in 2017. In 2021, he was named President of the company. In his roles, Bart oversaw finance, business development, commercial strategy, human resource
- GlobeNewswire
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA (r-AxSpA) and non-radiographic AxSpA (nr-AxSpA)Results from Phase 2 TORTUGA study showed that filgotinib 200mg was efficacious and well-tolerated in patients with r-AxSpAFilgotinib, an oral, once-daily JAK1 preferential inhibitor, is currently approved in Europe and Japan for the treatment of rheum
- GlobeNewswire
Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
Mechelen, Belgium; 25 April 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces the approval of all resolutions proposed at its annual shareholders’ meeting (AGM) held today at 14.00 CET. The AGM approved, amongst other items, the re-appointments of Mr. Peter Guenter as non-executive independent director for a period of 4 years, and of Mr. Daniel O’Day and Dr. Linda Higgins as non-executive non-independent directors for a period of 4 years, all effective as of todaythe appoin
- Simply Wall St.
Galapagos NV (AMS:GLPG) Looks Inexpensive But Perhaps Not Attractive Enough
Galapagos NV's ( AMS:GLPG ) price-to-sales (or "P/S") ratio of 4.5x might make it look like a strong buy right now...
- GlobeNewswire
Galapagos and NovAliX enter into an integrated drug discovery collaboration
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (CRO) based in Strasbourg, FranceNovAliX to assume Galapagos’ research capabilities, and Galapagos retains flexibility to access necessary expertise and resources through a five year-collaboration agreementTransaction in the context of Galapagos’ strategic reset announced in 2022; closing expected in July 2023 Mechelen, Belgium and Strasbourg, Fr
- GlobeNewswire
Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting
Publication of annual report for financial year 2022Annual Shareholders’ Meeting proposed resolutions include re-appointment of Board members and appointment of new statutory auditor Mechelen, Belgium; 23 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2022 and announces its Annual Shareholders’ Meeting, to be held on Tuesday 25 April 2023, at 2:00 p.m. (CET), at the registered office of the company. T
- GlobeNewswire
Galapagos increases share capital through subscription right exercises
Mechelen, Belgium; 20 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 61,560 new ordinary shares on 20 March 2023, for a total capital increase (including issuance premium) of EUR 1,769,850.00. In accordance with Belgian transparency legislation1, Galapagos also wishes to note that its total share capital currently amounts to EUR 356,444,938.61, the total number of
- GlobeNewswire
Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Six presentations demonstrate Galapagos’ commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib, an oral, once daily, JAK1 preferential inhibitor) will be presentedSELECTIONLTE showed that filgotinib maintained a consistent safety profile; symptomatic remission rates and health-related quality of life (HRQoL) improved in patients with moderate to severe active ulcerative colitis (UC)
- Simply Wall St.
Earnings Release: Here's Why Analysts Cut Their Galapagos NV (AMS:GLPG) Price Target To €47.62
Galapagos NV ( AMS:GLPG ) just released its latest full-year report and things are not looking great. It was a pretty...
- GlobeNewswire
Galapagos announces full year 2022 results and outlook for 2023
Key 2022 and post-period events Dr. Paul Stoffelsi appointed as Chief Executive Officer and Chairman of the Board of DirectorsImplemented new strategic direction to accelerate innovation and time-to-patients: Set-up of new innovation model and fit-for-purpose R&D organizationFocus on key therapeutic areas of immunology and oncologyDiscontinuation of activities in fibrosis and kidney diseaseExpansion of drug modalities beyond small molecules, including biologicals and CAR-T Entered into the field
- GlobeNewswire
Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL
All 7 out of 7 eligible patients with relapsed/refractory Chronic Lymphocytic Leukemia, with or without Richter’s transformation, responded to treatment (Objective Response Rate of 100%)GLPG5201 showed an acceptable safety profile with no cytokine release syndrome (CRS) higher than grade 2, or immune effector cell-associated neurotoxicity syndrome (ICANS) observed Mechelen, Belgium; 9 February 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today presented encouraging data at the Europea
- GlobeNewswire
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints of clinical remission and endoscopic response at Week 58The safety findings were generally consistent with the known profile of filgotinib in rheumatoid arthritis (RA) and ulcerative colitis (UC)Galapagos decided not to submit a Marketing Authorization Application in Europe based on these topline
- GlobeNewswire
Galapagos receives transparency notification from FMR LLC
Mechelen, Belgium; 10 January 2023, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 9 January 2023 from FMR LLC, who notified that it holds 3,903,804 of Galapagos’ voting rights, consisting of 3,801,504 ordinary shares and 102,300 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management & Resea
- GlobeNewswire
Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
Mechelen, Belgium; 3 January 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 41th Annual J.P. Morgan Healthcare Conference on January 9-12, 2023. Paul Stoffels1, CEO, will present on Monday, January 9 at 4.30 p.m. PST/7.30 p.m. ET (Tuesday, January 10 at 01.30 a.m. CET). The presentation will be a live audio webcast and can be accessed via the following link. A replay of the webcast will be available on the Galapagos’ website at https://www.glpg.com/webcasts. Abou
Zacks3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
- GlobeNewswire
Galapagos announces changes to Executive Committee
Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the Executive Committee effective 1 January 2023. Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. He will stay with Galapagos until 31 May 2023 to ensure a smooth transition. The company also announces the retirement of André Hoekema who joined Galapagos in 2005 as Chief Business Off
- Simply Wall St.
Following a 20% decline over last year, recent gains may please Galapagos NV (AMS:GLPG) institutional owners
To get a sense of who is truly in control of Galapagos NV ( AMS:GLPG ), it is important to understand the ownership...
ZacksDoes Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 34.4% in Galapagos NV (GLPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- GlobeNewswire
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
6 out of 7 eligible patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) responded to treatment (ORR of 86%) and all responding patients achieved complete response (CR)No grade 3 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in any of the eligible patientsInitial data suggest the potential of our decentralized manufacturing and supply model for faster, convenient, and efficient delivery of GLPG5101 at the point-